Gain Therapeutics Inc (GANX)
2.48
-0.03
(-1.20%)
USD |
NASDAQ |
May 21, 16:00
2.48
0.00 (0.00%)
After-Hours: 20:00
Gain Therapeutics Net Income (Quarterly): -4.014M for March 31, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -4.014M |
| December 31, 2023 | -4.724M |
| September 30, 2023 | -4.718M |
| June 30, 2023 | -7.688M |
| March 31, 2023 | -5.137M |
| December 31, 2022 | -4.674M |
| September 30, 2022 | -4.558M |
| June 30, 2022 | -5.085M |
| March 31, 2022 | -3.273M |
| Date | Value |
|---|---|
| December 31, 2021 | -3.220M |
| September 30, 2021 | -4.664M |
| June 30, 2021 | -3.557M |
| March 31, 2021 | -2.450M |
| December 31, 2020 | -1.656M |
| September 30, 2020 | -0.7944M |
| June 30, 2020 | -0.5434M |
| March 31, 2020 | -0.5843M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-7.688M
Minimum
Jun 2023
-0.5434M
Maximum
Jun 2020
-3.608M
Average
-4.014M
Median
Mar 2024
Net Income (Quarterly) Benchmarks
| Eli Lilly and Co | 2.243B |
| Alpine Immune Sciences Inc | -17.92M |
| Outlook Therapeutics Inc | -114.29M |
| OptiNose Inc | -14.07M |
| Greenwich LifeSciences Inc | -2.747M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 4.378M |
| EPS Diluted (Quarterly) | -0.22 |
| Enterprise Value | 33.16M |
| Earnings Yield | -60.48% |
| Normalized Earnings Yield | -65.30 |